Literature DB >> 23289841

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

S Rusconi1, P Vitiello, F Adorni, B Bruzzone, A De Luca, V Micheli, P Meraviglia, R Maserati, M Di Pietro, G Colao, G Penco, A Di Biagio, G Punzi, L Monno, M Zazzi.   

Abstract

Raltegravir (RAL) is the only licensed human immunodeficiency virus (HIV) integrase inhibitor. The factors associated with the virological response to RAL-containing regimens and the prevalence of integrase mutations associated with RAL failure deserve further investigation. From the Antiretroviral Resistance Cohort Analysis database, we selected triple-class-experienced subjects failing their current treatment with complete treatment history available. Selection criteria included HIV-RNA, CD4 count and HIV genotype within 3 months of RAL initiation. Factors associated with 24-week response were analysed; genotypic sensitivity scores (GSS) and weighted-GSS were evaluated. Virological response was achieved in 74.3% of 105 subjects. Mutations associated with RAL failure were detected in 12/24 subjects with an integrase genotype, with the prevalence of Q148H + G140S. Each extra unit of GSS (p 0.05, OR 2.62; 95% CI 1.00-6.87). was found to be a associated with response. Weighted-GSS had borderline statistical significance (p 0.063, OR 2.04; 95% CI 0.96-4.33) When stratifying for different cut-offs (<1 as reference, 1-1.49, ≥1.5), a borderline significant increase in the probability of response appeared for GSS ≥1.5 (p 0.053, OR 4.00; 95% CI 0.98-16.25). GSS ≥1 showed the highest sensitivity, 82.6%. Receiver operating characteristic curves depicted the widest area under the curve (0.663, p 0.054) of GSS ≥1. Unresponsiveness to RAL-containing regimens among triple-class-experienced subjects was low. The activity of the background regimen was strongly associated with response. Although few integrase genotypes were available at failure, half of these were without integrase resistance mutations. The substantial rate of RAL failure in the absence of known RAL-resistance mutations may be associated with adherence issues and this issue warrants further analysis in longer observations.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Drug resistance; genotype; human immunodeficiency virus type 1-1; raltegravir; virological response

Mesh:

Substances:

Year:  2013        PMID: 23289841     DOI: 10.1111/1469-0691.12100

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  3 in total

1.  Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.

Authors:  José Antonio Mata-Marín; Ariane Estrella Weiser Smeke; Mariana Rotzinger Rodriguez; Marcelino Chávez-García; Marco Isaac Banda-Lara; Alma Minerva Pérez Rios; Nohemí Nuñez-Rodríguez; Juan Carlos Domínguez-Hermosillo; Alberto Chaparro Sánchez; Irene Juarez-Kasusky; Javier Enrique Cruz Herrera; Jorge Luis Sandoval Ramírez; Jesús Gaytán-Martínez
Journal:  Drugs R D       Date:  2017-03

2.  Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach.

Authors:  Carlo Mengoli; Monica Basso; Samantha Andreis; Renzo Scaggiante; Mario Cruciani; Roberto Ferretto; Sandro Panese; Vinicio Manfrin; Daniela Francisci; Elisabetta Schiaroli; Gaetano Maffongelli; Loredana Sarmati; Massimo Andreoni; Franco Baldelli; Giorgio Palu'; Saverio Giuseppe Parisi
Journal:  PLoS One       Date:  2019-03-11       Impact factor: 3.240

3.  Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.

Authors:  Tomas Doyle; David T Dunn; Francesca Ceccherini-Silberstein; Carmen De Mendoza; Frederico Garcia; Erasmus Smit; Esther Fearnhill; Anne-Genevieve Marcelin; Javier Martinez-Picado; Rolf Kaiser; Anna Maria Geretti
Journal:  J Antimicrob Chemother       Date:  2015-08-26       Impact factor: 5.790

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.